SCHEMBL25733481

SCHEMBL25733481

Cn1c(-c2ccncc2)nc2c(N3CCOCC3)nc(-n3ccc(C4CCOC4)n3)nc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 10/20 0.37
▸ ALDH1A1 P00352 10/20 0.37
▸ HPGD P15428 10/20 0.37
▸ HSD17B10 Q99714 10/20 0.37
▸ CYP3A4 P08684 6/20 0.36
▸ PIK3CD O00329 4/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC10 Q969S8 1/20 0.36
▸ HDAC11 Q96DB2 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC9 Q9UKV0 1/20 0.36
▸ HDAC5 Q9UQL6 1/20 0.36
▸ NCOR2 Q9Y618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30254842 1.00 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733537 0.96 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31730977 0.96 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31730846 0.90 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733517 0.90 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31730933 0.89 KDM4E (0.36) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL31730892 0.89 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733383 0.89 KDM4E (0.36) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25733406 0.89 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL25274245 0.87 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 — — US disclosed
US-20240150358-A1 PURINES AND METHODS OF THEIR USE Kineta, Inc. 2024-05-09 — — US disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150358-A1 PURINES AND METHODS OF THEIR USE PNP, NUDT1, HPRT1 KDM4E 4105/4885ALDH1A1 1148/4885HPGD 593/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE KDM4E 870/4885ALDH1A1 4617/4885HPGD 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback